Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
WASHINGTON — The Food and Drug Administration is stepping up action against GlaxoSmithKline PLC over improper marketing of its popular diabetes drug Avandia, Thursday’s Wall Street Journal reported.
In a formal warning letter dated July 17, the FDA said it had learned that the company’s sales representatives, speaking with doctors at a recent medical conference, denied the existence of serious side effects Avandia users may experience. In a separate letter, the agency also told the company to stop airing a “misleading” television ad for Avandia.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in